Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth

Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025

The private funding rose 38% amid growing international collaborations and CDMO demand

Novartis locks in $23 billion US expansion with seventh new facility

The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics

Thermo Fisher to sell microbiology business in $1.075 billion deal with Astorg

The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026

Sun Pharma eyes biosimilars-led growth, Organon deal to build $12.4 billion global platform

On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms

Sun Pharma to acquire Organon in $11.75 billion all-cash deal

Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally

Merck & Google Cloud ink $1 billion AI deal to build “Agentic” pharma future

The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Syntegon reports record FY25 Results; revenue rises 10% to €1.75 billion

The company allocated €56 million to research and development for next-generation line solutions